CHRYSALIS Phase I Trial: Amivantamab + Lazertinib in Osimertinib-Relapsed, Chemotherapy-Naive EGFR-Mutated Advanced NSCLC, Including Analyses of Biomarkers of Response

Source: 2021 ASCO Virtual Annual Meeting*
Download Slideset
June 4-8, 2021; Online at https://conferences.asco.org/am
Amivantamab plus lazertinib achieved an ORR of 36% in chemotherapy-naive patients with disease progression on first-line osimertinib.
Format: Microsoft PowerPoint (.ppt)
File Size: 243 KB
Released: June 9, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings